[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594640":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":20,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":67,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Xijing Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"before-after study in the same patient","EXPERIMENTAL","About 69 patients with inflammatory bowel disease are planned to be included in this study. The screened subjects will undergo 68Ga-grazytracer PET\u002FCT imaging before and at 2 weeks after drug therapy, and the investigators will collect clinical information from the patients, collect blood samples for granzyme B levels, and analyse the imaging results for data analysis.",[13],"Diagnostic Test: 68Ga-grazytracer PET\u002FCT Scan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","68Ga-grazytracer PET\u002FCT Scan","The imaging agent 68Ga-grazytracer used in this project is synthesised in accordance with the standards for the production of radiopharmaceuticals with reference to the Chinese Pharmacopoeia (18F-FDG quality standard). pH value is between 5.0-8.0; radiochemical purity is not less than 95%, and the content of bacterial endotoxin per mL of solution is less than 15EU; the concentration of radioactivity is not less than 37MBq\u002FmL; the solvent The residual amount of solvent complies with the regulations. Specification: 185\\~1850 MBq\u002Fml Characteristics Colourless and transparent, no visible particles. Physical half-life: 68 minutes for 68Ga. Stable for 3 half-lives from the time of labelling. Method of administration: Intravenous. Dose: 0.05Ci\u002Fkg, followed by a 5 mL saline flush.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ying Guo Ying Guo","CONTACT","029-84771048","guoying01192022@163.com",[28],{"facility":29,"status":20,"city":30,"state":31,"zip":20,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China, Xi'an, Shaanxi Province","Xi'an","Shaanxi","China","CN",{"type":35,"coordinates":36},"Point",[37,38],108.92861,34.25833,{"lat":38,"lon":37},[41],{"name":23,"role":24,"phone":42,"phoneExt":20,"email":26},"02984771048",{"type":44,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100594640","evaluating-the-effectiveness-of-68ga-grazytracer-petct-in-inflammatory-bowel-disease-100594640",false,"NCT07022080","Evaluating the Effectiveness of 68Ga-grazytracer PET\u002FCT in Inflammatory Bowel Disease","68Ga-grazytracer PET\u002FCT Study in Inflammatory Bowel Disease","Inclusion Criteria:\n\n* Age between 18-80 years old; Clinical diagnosis of inflammatory bowel disease (active stage); Not having received treatment within 4 weeks prior to undergoing PET\u002FCT examination; Received endoscopy within 7 days before and after PET\u002FCT examination; Signing an informed consent form for PET\u002FCT examination and volunteering to participate in this study.\n\nExclusion Criteria:\n\n* No signed informed consent or unspecified diagnosis; Female subjects are pregnant or breastfeeding and male subjects are preparing for pregnancy; Those who are unfit to perform (concomitant severe and\u002For uncontrollable and\u002For unstable disease, developer allergy) or who are unable to complete imaging such as PET for specific reasons (needle-sickness, blood-sickness, claustrophobia); Colitis other than inflammatory bowel disease (infectious or ischaemic colitis); Patients who have undergone colon resection.","ALL","18 Years","80 Years",{"count":56,"type":57},69,"ESTIMATED","INTERVENTIONAL",[60],"NA","This is a single-centre, prospective, observational cohort study in which 69 patients with inflammatory bowel disease (IBD) were recruited to undergo 68Ga-grazytracer PET\u002FCT imaging in patients with IBD to investigate the feasibility of early sensitive detection or prediction of the response to medication in patients with inflammatory bowel disease on 68Ga-grazytracer PET\u002FCT and early prediction of the The feasibility of 68Ga-grazytracer PET\u002FCT for early detection or prediction of response to drug therapy and early prediction of long-term prognosis in patients with inflammatory bowel disease.",[63],"Inflammatory Bowel Diseases (IBD)",[65,66],"PET\u002FCT","68Ga-grazytracer","NOT_YET_RECRUITING","2025-06-08",{"date":70,"type":71},"2025-06-15","ACTUAL",{"date":70,"type":57},{"date":74,"type":57},"2027-12-31",{"name":5,"class":6},1]